TD Cowen downgrades Kronos Bio (KRON) to a Hold
Kronos Bio (KRON – Research Report) received a Hold rating and price target from TD Cowen analyst Tyler Van Buren yesterday. The ...
Business Insider14h
Positive Outlook for Oruka Therapeutics: Promising Developments with ORKA-001
Tyler Van Buren has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ promising developments with their lead antibody, ORKA-001. The extended half-life of ORKA-001, ...
manilatimes15h
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov. 13, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel ...